[{"symbol": "RVMD", "publishedDate": "2026-01-13 07:38:00", "publisher": "GuruFocus", "title": "First Look: Fed Probe, Bank Cap Shock, Gold Soars, Deals", "image": "https://images.financialmodelingprep.com/news/first-look-fed-probe-bank-cap-shock-gold-soars-20260113.png", "site": "gurufocus.com", "text": "Stock News DOJ subpoenas Fed chair spark backlash: Federal prosecutors served grand jury subpoenas to Jerome Powell over testimony on Fed HQ renovations, prompt", "url": "https://www.gurufocus.com/news/4107908/first-look-fed-probe-bank-cap-shock-gold-soars-deals"}, {"symbol": "RVMD", "publishedDate": "2026-01-12 17:26:01", "publisher": "Seeking Alpha", "title": "Revolution Medicines, Inc. (RVMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript", "image": "https://images.financialmodelingprep.com/news/revolution-medicines-inc-rvmd-presents-at-44th-annual-jp-20260112.jpg", "site": "seekingalpha.com", "text": "Revolution Medicines, Inc. (RVMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript", "url": "https://seekingalpha.com/article/4858914-revolution-medicines-inc-rvmd-presents-at-44th-annual-j-p-morgan-healthcare-conference"}, {"symbol": "RVMD", "publishedDate": "2026-01-12 01:10:51", "publisher": "Defense World", "title": "Revolution Medicines, Inc. (NASDAQ:RVMD) Given Average Rating of \u201cBuy\u201d by Analysts", "image": "https://images.financialmodelingprep.com/news/revolution-medicines-inc-nasdaqrvmd-given-average-rating-of-buy-20260112.png", "site": "defenseworld.net", "text": "Shares of Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) have been given an average rating of \"Buy\" by the eighteen research firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, thirteen have given a buy recommendation and four have assigned a strong buy", "url": "https://www.defenseworld.net/2026/01/12/revolution-medicines-inc-nasdaqrvmd-given-average-rating-of-buy-by-analysts.html"}, {"symbol": "RVMD", "publishedDate": "2026-01-11 08:01:45", "publisher": "Benzinga", "title": "Sandisk, Bloom Energy, And Oklo Are Among the Top 10 Large-Cap Gainers Last Week (Jan. 5-Jan. 9): Are the Others in Your Portfolio?", "image": "https://images.financialmodelingprep.com/news/sandisk-bloom-energy-and-oklo-are-among-the-top-20260111.jpeg", "site": "feeds.benzinga.com", "text": "Defense, AI power demand and deal-driven catalysts powered last week's top large-cap winners, led by sharp surges in RGC, RVMD and a cluster of defense and data-center energy plays.", "url": "https://www.benzinga.com/markets/equities/26/01/49831544/sandisk-bloom-energy-and-oklo-are-among-the-top-10-large-cap-gainers-last-week-jan-5-jan-9-are-t"}, {"symbol": "RVMD", "publishedDate": "2026-01-11 05:12:42", "publisher": "Defense World", "title": "Jack Anders Sells 10,000 Shares of Revolution Medicines (NASDAQ:RVMD) Stock", "image": "https://images.financialmodelingprep.com/news/jack-anders-sells-10000-shares-of-revolution-medicines-nasdaqrvmd-20260111.png", "site": "defenseworld.net", "text": "Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) CFO Jack Anders sold 10,000 shares of Revolution Medicines stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $98.00, for a total value of $980,000.00. Following the sale, the chief financial officer owned 108,065 shares in the company, valued", "url": "https://www.defenseworld.net/2026/01/11/jack-anders-sells-10000-shares-of-revolution-medicines-nasdaqrvmd-stock.html"}, {"symbol": "RVMD", "publishedDate": "2026-01-09 19:56:16", "publisher": "The Motley Fool", "title": "Why Revolution Medicines Stock Surged by 11% Today", "image": "https://images.financialmodelingprep.com/news/why-revolution-medicines-stock-surged-by-11-today-20260109.jpg", "site": "fool.com", "text": "It's apparently in talks to be sold to a pharmaceutical industry titan. The price being discussed reaches into the tens of billions of dollars.", "url": "https://www.fool.com/investing/2026/01/09/why-revolution-medicines-stock-surged-by-11-today/"}, {"symbol": "RVMD", "publishedDate": "2026-01-09 16:46:53", "publisher": "Benzinga", "title": "Deal Dispatch: Saks Faces A Luxury Liquidity Crisis, Soho House Gets Quiet", "image": "https://images.financialmodelingprep.com/news/deal-dispatch-saks-faces-a-luxury-liquidity-crisis-soho-20260109.jpeg", "site": "feeds.benzinga.com", "text": "Dealmaking persists as creditors, buyers, and investors wrestle with debt, delays, and mega-merger ambitions.", "url": "https://www.benzinga.com/m-a/26/01/49826706/deal-dispatch-saks-faces-a-luxury-liquidity-crisis-soho-house-gets-quiet"}, {"symbol": "RVMD", "publishedDate": "2026-01-09 14:58:00", "publisher": "WSJ", "title": "Merck is in talks to acquire Revolution Medicines in a deal that could value the cancer-drug biotech at around $30 billion", "image": "https://images.financialmodelingprep.com/news/merck-is-in-talks-to-acquire-revolution-medicines-in-20260109.jpg", "site": "wsj.com", "text": "Revolution is developing drugs that target a molecular driver of cancers.", "url": "https://www.wsj.com/health/pharma/merck-in-talks-to-buy-revolution-medicines-for-around-30-billion-13f798a1"}, {"symbol": "RVMD", "publishedDate": "2026-01-09 14:33:26", "publisher": "Seeking Alpha", "title": "Revolution Medicines: \"Strong Buy\" As Acquisition Prospects Continue To Circle", "image": "https://images.financialmodelingprep.com/news/revolution-medicines-strong-buy-as-acquisition-prospects-continue-to-20260109.jpg", "site": "seekingalpha.com", "text": "Revolution Medicines (RVMD) remains a \"Strong Buy\", driven by advanced RAS [ON] inhibitor programs and robust clinical progress, notably with Daraxonrasib. Company's phase 3 RASolute-302 trial in metastatic PDAC RAS-mutant patients is a major catalyst, with data expected in 2026 and significant expansion potential. Buyout interest from major pharma, including rumored $28\u201332B bids, underscores RVMD's strategic value and enhances upside optionality.", "url": "https://seekingalpha.com/article/4858444-revolution-medicines-strong-buy-as-acquisition-prospects-continue-to-circle"}, {"symbol": "RVMD", "publishedDate": "2026-01-09 13:06:06", "publisher": "Zacks Investment Research", "title": "Merck in Talks to Buy Revolution Medicines Per Financial Times Report", "image": "https://images.financialmodelingprep.com/news/merck-in-talks-to-buy-revolution-medicines-per-financial-20260109.jpg", "site": "zacks.com", "text": "Merck is in talks to acquire RVMD, which could bolster its oncology pipeline, according to a Financial Times report.", "url": "https://www.zacks.com/stock/news/2815199/merck-in-talks-to-buy-revolution-medicines-per-financial-times-report?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2815199"}]